deltatrials
Terminated PHASE3 NCT00811967

Inhibition of Disease Progression in Hepatitis C-infected Patients With Compensated Liver Cirrhosis (P03811) (COMPLETED)

Inhibition of Disease Progression in Hepatitis C-infected Patients With Compensated Liver Cirrhosis

Sponsor: Merck Sharp & Dohme LLC

Conditions Hepatitis C, Chronic Liver Cirrhosis
Interventions PegIntron (peginterferon alfa-2b; SCH 54031) Rebetol (ribavirin; SCH 18908)
Updated 7 times since 2017 Last updated: Mar 8, 2017 Started: Feb 28, 2003 Primary completion: May 31, 2006 Completion: May 31, 2006

Listed as NCT00811967, this PHASE3 trial focuses on Hepatitis C, Chronic and Liver Cirrhosis and remains terminated or withdrawn. Sponsored by Merck Sharp & Dohme LLC, it has been updated 7 times since 2003, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Change History

7 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE3

  3. Jun 2022 — Jul 2024 [monthly]

    Terminated PHASE3

  4. Jan 2021 — Jun 2022 [monthly]

    Terminated PHASE3

  5. Jun 2018 — Jan 2021 [monthly]

    Terminated PHASE3

▶ Show 2 earlier versions

  1. Feb 2017 — Jun 2018 [monthly]

    Terminated PHASE3

  2. Jan 2017 — Feb 2017 [monthly]

    Terminated PHASE3

    First recorded

Feb 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Merck Sharp & Dohme LLC
Data source: Merck Sharp & Dohme LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.